NEW YORK, NY / ACCESSWIRE / July 15, 2016 / Pomerantz LLP announces that a class action lawsuit has been filed against Immunomedics, Inc. (“Immunomedics” or the “Company”) (NASDAQ: IMMU) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Immunomedics securities between April 20, 2016 and June 2, 2016 inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

If you are a shareholder who purchased Immunomedics securities during the Class Period, you have until August 8, 2016 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.

[Click here to join this class action]

Immunomedics, a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases. Among other product candidates, the Company is developing the antibody-drug conjugate sacituzumab govitecan IMMU-132 (“IMMU-132”), which is in Phase II trials for treatment of patients with metastatic triple-negative breast cancer and small-cell and non-small-cell lung cancers.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the abstract for IMMU-132 that Immunomedics submitted to the American Society of Clinical Oncology (“ASCO”) for presentation at the 2016 ASCO Annual Meeting contained previously disclosed results from a mid-stage study; (ii) Immunomedics had misrepresented to ASCO that its abstract for IMMU-132 contained only updated and previously undisclosed data; (iii) the foregoing misrepresentation was a violation of ASCO policy and made Immunomedics’ IMMU-132 presentation subject to removal from the 2016 ASCO Annual Meeting schedule; and (iv) as a result of the foregoing, Immunomedics’ public statements were materially false and misleading at all relevant times.

On April 19, 2016, Immunomedics announced that the Company would present updated results for its IMMU-132 treatment at ASCO’s Annual Meeting in June 2016.

On June 2, 2016, after the market closed, media outlets reported that ASCO had removed a scheduled presentation by Immunomedics regarding the Company’s IMMU-132 breast cancer drug from ASCO’s annual meeting. ASCO stated that Immunomedics had misrepresented that the Company’s abstract for IMMU-132 contained updated and previously undisclosed results from a mid-stage study, when in fact the IMMU-132 data that Immunomedics submitted were old and previously seen.

As a result of this news, Immunomedics shares fell $0.78, or 14.72%, to close at $4.52 on June 3, 2016.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP&

ReleaseID: 442462

BALA CYNWYD, PA / ACCESSWIRE / July 15, 2016 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Sagent Pharmaceuticals, Inc. (“Sagent” or “the Company”) (NASDAQ: SGNT) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Nichi-Iko Pharmaceutical Co., Ltd. (“Nichi-Iko”).

Click here to learn more about the investigation
http://brodsky-smith.com/1100-sgnt-sagent-pharmaceuticals-inc.html, or call: 877-534-2590. There is no cost or obligation to you.

Under the terms of the transaction, Sagent shareholders will receive only $21.75 in cash for each share of Sagent stock they own. The investigation concerns whether the Board of Sagent breached their fiduciary duties to shareholders and whether Sagent is underpaying for the Company. The transaction may undervalue the Company and would result in a loss for many long-term holders of Sagent stock. For example Sagent stock traded at $32.81 per share on October 13, 2014 and $26.19 per share on July 14, 2015. In addition, an analyst has set a price target for Sagent stock at $25.00 per share.

If you own shares of Sagent stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, by visiting http://brodsky-smith.com/1100-sgnt-sagent-pharmaceuticals-inc.html, or calling toll free 877-LEGAL-90.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE: Brodski & Smith, LLC

ReleaseID: 442458

VANCOUVER, BC / ACCESSWIRE / July 15, 2016 / Castle Peak Mining Ltd. (TSXV: CAP) (“Castle Peak” or the “Company”) reports that its board of directors has authorized an amendment to the expiry date and reduce the exercise price of certain warrants issued in connection with the Company’s private placement which closed on July 10, 2013.

Pursuant to the private placement, an aggregate of 40,000,000 warrants were issued bearing an original expiry date of July 17, 2016 and an exercise price of $0.10 per share, all of which remain unexercised.

The Company is now seeking the approval of the TSX Venture Exchange to extend the expiry date of 20,000,000 of these warrants to December 31, 2017 (the “Amended Warrants”). The 20,000,000 warrants not being extended will expire on July 17, 2016.

The Company is also seeking approval of the TSXV Venture Exchange to reduce the exercise price of the Amended Warrants to $0.05 per share or such other price as may be acceptable to the TSX Venture Exchange.

The Amended Warrants are held by parties who are considered to be “related parties” of the Company. Therefore, the amendment of the Amended Warrants constitutes a “related party transaction” as contemplated by Multilateral Instrument 61-101 Protection of Minority Shareholders in Special Transactions, and TSXV Policy 5.9 – Protection of Minority Shareholders in Special Transactions. However, the exemptions from formal valuation and minority approval requirements provided for by these guidelines can be relied upon because neither the fair market value of the Amended Warrants nor the fair market value of the consideration paid for the Amended Warrants exceeds 25% of the market capitalization of the Company. A material change report in respect of this related party transaction will be filed by the Company. The material change report could not be filed earlier than 21 days prior to the amendment of the Warrants due to the pending expiry of such warrants.

About Castle Peak

Castle Peak Mining Ltd. is a Canadian-based junior exploration company focused on advancing greenfields and early stage gold projects. The Company holds a strategic land package in the Ashanti belt adjacent to several producing gold mines in Ghana, West Africa. The Ashanti belt is known as one of the most prolific gold belts in the world.

On behalf of the Board of Castle Peak Mining Ltd.:

“Darren Lindsay“
President and Chief Executive Officer

For additional information please visit www.castlepeakmining.com or contact:

Darren Lindsay, President and CEO
Tel: 604 345 1926
Email: darrenl@castlepeakmining.com

FORWARD-LOOKING STATEMENTS

Except for statements of historical fact, this news release contains certain ‘forward-looking information’ and ‘forward-looking statements’ within the meaning of applicable securities laws including statements regarding the Offering and the proposed use of proceeds. Such forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to known and unknown risks, uncertainties and assumptions that could cause actual results to vary materially from the anticipated results or events predicted in these forward-looking statements, including those risk factors identified in the Company’s Filing Statement filed under the Company’s SEDAR profile. As a result, readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this release. Except as required by applicable law, Castle Peak disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES

SOURCE: Castle Peak Mining Ltd.

ReleaseID: 442461

VANCOUVER, BC / ACCESSWIRE / July 15, 2016 / M Pharmaceutical, Inc. (CSE: MQ, OTC: MPHMF, FSE: T3F2.F), (the “Company” or “M Pharma”), has closed on its previously announced (April 6, 2016) agreement to acquire assets from Chelatexx, LLC related to a reformulated version of orlistat (product “C-103”). The addition of C-103 provides a novel weight loss pharmaceutical product to the M Pharma pipeline.

The Company paid an up-front cash payment of US$ 200,000, has issued 10 million common shares at a deemed price of $0.10 per share, and will pay a low single-digit royalty on net sales. 10% of the common shares issued will be subject to trading restrictions until November 8, 2016. The balance of the common shares issued are subject to an escrow agreement that will have them released over the 3 years from the date of closing.

Brian Keane, president of the Company, remarked, “We are pleased that this transaction has now closed. Our next step is to finalize a development plan to move both this product and our Trimeo project into clinical trials and regulatory approvals. We see both these products providing much needed solutions to the current obesity problem.”

Gary Thompson, president of Chelatexx LLC, said, “We are very excited to partner with a company so passionate about delivering weight loss solutions to a global market of almost 2 billion adults. Worldwide obesity has doubled since 1980 and now effects 41 million children under the age of 5. Using our patented Chelatexx technology, M-Pharma will be able to launch a reformulated Orlistat into a global market estimated to reach $7.8 billion by 2021.”

Background information on Orlistat

Orlistat is currently marketed in prescription strength by Roche Laboratories, Inc. (Xenical® 120mg capsules) and in over-the-counter strength by GlaxoSmithKline Consumer Healthcare (alli® 60mg capsules). Orlistat has proven safe and effective in numerous clinical trials and remains the only FDA-approved weight management drug for a pediatric population (adolescents 12 years and older). Orlistat does not affect the central nervous system and it is not systemically absorbed, as compared to other approved weight management drugs.

Recent sales of orlistat have declined from its peak due to uncomfortable and well-publicized side effects of the product. The development goal of the C-103 reformulation is to maintain the proven efficacy of orlistat while minimizing or eliminating the undesirable side effects. Chelatexx, LLC holds issued U.S. patents covering C-103 technology until 2030. The U.S. Food and Drug Administration has confirmed in writing that C-103 is eligible for 505(b)(2) approval in the U.S., under which the FDA is permitted to rely, for approval of the new drug, on data not developed by the applicant – such as published literature or the FDA’s finding of safety and/or effectiveness of a previously approved drug product. The Company cautions that there is no guarantee that C-103 will achieve its development goals and that there are no guarantees that C-103 will be approved by any health regulatory agency.

About M Pharmaceutical Inc.

Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for obesity and weight management. In addition to the intended acquisition of C-103 from Chelatexx, LLC, the Company will focus on the development of its Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity, for which it has exclusive rights.

M Pharmaceutical trades on the Canadian Securities Exchange (CSE) under the ticker symbol “MQ” as well as on the OTC as “MPHMF” and FSE (Frankfurt Stock Exchange) as “T3F2.”

For more information, contact:
Investor Relations
Phone: +1 604 428 0511
info@m-pharma.ca
www.m-pharma.ca

ON BEHALF OF THE BOARD OF DIRECTORS
/s/ “Brain Keane, BSc”
Interim President and CEO

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate,” “continue,” “estimate,” “expect,” “may,” “will,” “project,” “should,” “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the commercialization of the rights to the its biomedical technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and the Company’s filings to the CSE at www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

SOURCE: M Pharmaceutical Inc.

ReleaseID: 442451

INDIANAPOLIS, IN / ACCESSWIRE / July 15, 2016 / Noble Roman’s, Inc. (OTCQB: NROM), the Indianapolis based franchisor and licensor of Noble Roman’s Pizza and Tuscano’s Italian Style Subs, today announced that Mr. Marcel Herbst has been appointed in substitution for Schuster Tanger to its Board of Directors. Mr. Herbst, will assume the Class I Director position, the term of which will expire at the 2017 Annual Meeting of the Shareholders.

Mr. Herbst, a holder of the Chartered Financial Analyst® designation, is the founder and portfolio manager of Herbst Capital Management, LLC and has over 15 years of investment experience in equities, fixed income and commodities. Mr. Herbst started his professional career in Germany with a Commercial Diploma in Banking. Prior to founding Herbst Capital Management, LLC, Mr. Herbst had more than 10 years experience in the management of hospitality services for large, upscale, branded properties in the US and Europe. Most recently he served as the Director of Food and Beverage at the 1544 room Hilton Chicago, overseeing $40M in annual food and beverage revenue. Mr. Herbst has a Bachelor degree of Business Administration from Schiller International University in Heidelberg, Germany and a Master’s degree of Management in Hospitality concentrating in food and beverage from Cornell University.

Pursuant to an agreement dated April 8, 2015, by and among Noble Roman’s, Inc. and Red Alder GP, LLC; Red Alder GP, LLC and other related parties (“Shareholder Parties”) have the right to recommend a substitute person to serve on the board of directors as a replacement director for Mr. Tanger. The Shareholder Parties have recommended Mr. Marcel Herbst as such a replacement director and the board of directors has unanimously agreed.

“We are excited to have someone of Mr. Herbst’s stature, financial ability and experience in the foodservice industry joining our board of directors,” said Mr. Scott Mobley, President and CEO of Noble Romans, Inc. “Mr. Herbst’s extensive knowledge and experience in both the financial and the foodservice industries should prove to be a tremendous asset to the company.”

When asked about his appointment to the board of directors of Noble Roman’s, Mr. Herbst said, “I am excited to join the Noble Roman’s board of directors. Noble Roman’s is well poised for significant long-term success with its notable strong product, strong executive team, and viable channels of growth. I look forward to collaborating with my fellow directors and the Noble Roman’s management team to continue to create value for all stockholders.”

The statements contained in this press release concerning the company’s future revenues, profitability, financial resources, market demand and product development are forward-looking statements (as such term is defined in the Private Securities Litigation Reform Act of 1995) relating to the company that are based on the beliefs of the management of the company, as well as assumptions and estimates made by and information currently available to the company’s management. The company’s actual results in the future may differ materially from those projected in the forward-looking statements due to risks and uncertainties that exist in the company’s operations and business environment, including, but not limited to, competitive factors and pricing pressures, non-renewal of franchise agreements, shifts in market demand, the success of new franchise programs with limited operating history including the stand-alone take-n-bake locations, general economic conditions, changes in purchases of or demand for the company’s products, licenses or franchises, the success or failure of individual franchisees and licensees, changes in prices or supplies of food ingredients and labor, and dependence on continued involvement of current management. Should one or more of these risks or uncertainties materialize, or should underlying assumptions or estimates prove incorrect, actual results may differ materially from those described herein as anticipated, believed, estimated, expected or intended. The company undertakes no obligations to update the information in this press release for subsequent events.

FOR ADDITIONAL INFORMATION, CONTACT:

For Media Information: Scott Mobley, President & CEO 317/634-3377
For Investor Relations: Paul Mobley, Executive Chairman 317/634-3377

SOURCE: Noble Roman’s, Inc.

ReleaseID: 442457

VANCOUVER, BC / ACCESSWIRE / July 15, 2016 / CIBT Education Group Inc. (TSX: MBA, OTCQX: MBAIF) (“CIBT” or the “Company”) is pleased to report that it has filed its consolidated financial statements and related Management’s Discussion and Analysis for its third quarter ending May 31, 2016. To review the filing, please visit CIBT’s profile on the SEDAR website (www.sedar.com).

“We are very pleased with our Q3 results as they reflect our commitment to successfully integrate our legacy education business with our fast growing and profitable student housing business,” said Toby Chu, President and CEO, Vice Chairman of CIBT. “In particular, our education revenues grew steadily at 2% during the first 9 months of the fiscal year while our rental revenue grew at a rate of 281% primarily as a result of our GEC managed downtown properties having near 100% occupancy since their acquisitions. Among the five GEC properties, we saw significant increases in property value across our entire portfolio. For the Q3 financial results, a conservative approach was taken and only two of the five properties’ increased values were included at a discount to current market value.”

“Our strategy remains focused on providing a channel for our domestic and international students to find affordable, safe and comfortable housing while we continue to grow our bed count in a market that remains very underserved,” continued Toby Chu. “In addition to the growth of our student housing portfolio, we remain active in acquiring undervalued education assets that will allow us to continue educating thousands of students across the province while growing our student housing pipeline.”

“For the remainder of 2016, the Company intends to continue to leverage its existing student resources to channel them into the GEC student housing portfolio. We anticipate having more than 400 beds available by the fall of 2016 and nearly 1,000 beds by spring 2017, thus providing us with stabilized long-term rental revenue. In addition to our housing portfolio, we expect our education assets to continue to generate stable revenue for the years to come.”

Highlights of the financial results are shown below. Please refer to the consolidated financial statements for the nine months ended May 31, 2016 and related Management’s Discussion and Analysis filed on SEDAR for complete details.

Noteworthy highlights for the nine month period ended May 31, 2016 with prior year comparative period results are as follows:

• Total revenue increased to $27.28 million from $23.40 million (+17%)
• Rental revenue increased to $1.44 million from $0.38 million (+281%)
• Development fee revenue increased to $3.62 million from $1.13 million (+220%)
• Net income increased to $10.01M from $2.03M (+394%)
• Net Income attributable to CIBT shareholders increased to $4.94 million from $26,937
• Earnings per share attributable to CIBT shareholders was $0.07 per share from $0.00
• EBITDA (Earnings Before Interest Tax Depreciation Amortization) increased to $11.05 million from $3.35M (+230%)
• Normalized EBITDA net of Non-recurring Expenses increased to $11.55 million from $3.59M (+222%)
• Total Assets increased to $100.85 million from $73.67 million, an increase of $27.19 million (+37%)
• Long Term Liabilities increased to $25.60 million from $24.17 million, an increase of $1.43 million (+6%)

Please note that Gain on Fair Value on only two out of the five properties in our portfolio were included in this 3rd quarter report. Any Gain on Fair Value on the remaining three properties in the GEC portfolio will be included in future reports as these projects are completed and possession is taken. If the current real estate market trends continue and or stabilize, then it is currently anticipated that Gain on Fair Value changes for the remaining three properties will be added to our future reports in coming quarters.

About CIBT Education Group:

CIBT Education Group Inc. is an education management company focused on the global education market since 1994. Listed in Canada on the Toronto Stock Exchange and in the U.S. on the OTCQX International, CIBT owns and operates a network of business, technical and language colleges in North America and Asia. CIBT offers cooperative joint programs in 12 countries with campuses, recruitment offices and training centers enrolling over 8,300 students annually. Its education business is operated through Sprott Shaw College (established in 1903), Acsenda School of Management, Vancouver International College, CIBT School of Business China, and Global Education Alliance Recruitment Centers at various overseas countries. Through these subsidiaries, CIBT offers recognized and approved business and management degrees, programs in college preparation, healthcare, hotel management and tourism, English language training, English Teacher Certifications, junior and high school preparation programs for overseas study, and other career/vocational training. CIBT also owns Irix Design Group, a leading design and advertising company based in Vancouver, Canada, Global Education Alliance and Global Education City Holdings Inc. Global Education Alliance recruits international students for many elite kindergarten, primary, secondary schools and universities in North America. GEC is an investment holding and management company with a special focus on education related real estate projects in Canada. Visit us online at www.cibt.net, www.studenthotel.ca, and watch our corporate video at http://cibt.net/about/.

Toby Chu
Vice-Chairman, President & CEO
CIBT Education Group Inc.
Investor Relations Contact: 1-604-871-9909 extension 318 or | Email: info@cibt.net

FORWARD-LOOKING STATEMENTS:

Some statements in this news release contain forward-looking information (the “forward-looking statements”) about CIBT Education Group Inc. and its future plans. Forward-looking statements are statements that are not historical facts. The forward-looking statements are subject to various risks, uncertainties and other factors that could cause CIBT’s actual results or achievements to differ materially from those expressed in or implied by forward-looking statements, including but not limited to obtaining all necessary regulatory approvals. Forward-looking statements are based on the beliefs, opinions and expectations of CIBT’s management at the time they are made, and CIBT does not assume any obligation to update its forward-looking statements if those beliefs, opinions or expectations, or other circumstances should change, except as may be required by law.

SOURCE: CIBT Education Group Inc.

ReleaseID: 442455